Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 8/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500953 | 0.89 | CASR (0.46) | CASRADRB2ADRB3HPGDADRB1 | |
| SCHEMBL354792 | 0.79 | HPGD (0.38) | CASRADRB2HPGDADRB1GHSR | |
| SCHEMBL5504082 | 0.78 | CASR (0.39) | CASRADRB2HPGDADRB1NPC1 | |
| SCHEMBL5506849 | 0.74 | GHSR (0.39) | CASRHPGDADRB1GHSRNPC1 | |
| SCHEMBL6008629 | 0.72 | CASP7 (0.40) | ADRB2ADRB3ADRB1SMN1; SMN2 | |
| SCHEMBL6010000 | 0.69 | CASR (0.42) | CASRADRB2HPGDADRB1GHSR | |
| SCHEMBL6009956 | 0.69 | HPGD (0.36) | CASRHPGDADRB1GHSRNPC1 | |
| SCHEMBL6008635 | 0.69 | GRIA4 (0.40) | ADRB2ADRB3ADRB1SMN1; SMN2 | |
| SCHEMBL10232031 | 0.68 | ESR1 (0.43) | ADRB2ADRB1GHSR | |
| SCHEMBL10889941 | 0.68 | ADRB2 (0.57) | CASRADRB2ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828111-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006059252-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | CASR 3333/4885ADRB2 867/4885ADRB3 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.